Back

Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis

31 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Prognostication and treatment of transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mazen Hanna

Cleveland Clinic Main Campus, Cleveland (United States of America)

7 More presentations in this session

Presentation thumbnail
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
When to stop? Real-world decision pathways for transthyretin stabilizer discontinuation in cardiac amyloidosis
Doctor K. Knoll (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Impaired right ventricular free wall strain predicts mortality in patients with stabilizer-treated transthyretin amyloid cardiomyopathy.
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy
Doctor A. Mejren (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Identifying predictors and cutoff values for pacemaker implantation in ATTR patients
Doctor S. Istratoaie (Cluj Napoca, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Prognostication and treatment of transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

31 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of Tafamidis on survival in elderly patients in a real-world setting: insights from the Healthcare European Amyloidosis Registry
thumbnail
Congress Presentation
Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Survival analysis of tafamidis use in patients with ATTR cardiac amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources